Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05748704
Status:
RECRUITING
Last Update Posted:
2023-03-01
First Post:
2022-10-19
Brief Title:
Metabolic and Immunological Effects of a Modified Fasting Regimen in Cancer Patients
Sponsor:
University of Genova
Organization:
University of Genova
Study Overview
Official Title:
Phase I II Single Arm Study Metabolic and Immunological Effects of a Modified Fasting Regimen in Cancer Patients
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm prospective pilot study assessing the metabolic and immunologic effects of a modified fasting regimen in cancer patients with different cancer types and concomitant anticancer treatment
Detailed Description:
A single-arm phase II clinical trial of a short-term modified fasting regimen STMF is proposed to be conducted in 100 patients with solid tumors who are candidates to receive active medical or radiotherapy treatment or with medical treatment or radiotherapy already ongoing Cancer treatment can be adjuvant or palliative Patients with haematological tumors are also included Enrolment is also foreseen for patients with haematological tumors who are not undergoing active treatment yet but are followed with a watchful waiting approach eg patients with low-risk B-CLL or low-risk follicular lymphoma Finally enrolment is also open to patients with relapsing forms of non-melanoma skin cancers eg basalioma epithelioma
The primary endpoint of the study is to evaluate the effects of a STMF on the circulating levels of factors with pro- or anti-oncogenic activity including insulin IGF1 IGFBP1 IGFBP3 leptin adiponectin IL-6 TNF-alpha IL1beta as well as the effect of STMF cycles on leukocyte subpopulations with a role in the control of tumor growth such as regulatory T cells the myeloid-derived suppressor cells MDSC as well as NK cells and on stem cell pools eg hematopoietic stem cells endothelial stem cells mesenchymal stem cells
The STMF regimen that is applied is a 5-day low-calorie and low-protein diet Patients undergo a medical examhistory collection and a nutritional assessment body weight handgrip strenght and bioimpedance measurement at baseline and then at the visits that precede every cycle of STMF ie once every three weeks or monthly depending on the therapeutic regimen the patient is undergoing and in any case no more frequently than once every three weeks - eg when combined with q21 chemotherapy regimens Adverse events are recorded at each visit in accordance with NCI-CTCAE version 50 P
The primary endpoint of the study is to evaluate the effects of a STMF on the circulating levels of factors with pro- or anti-oncogenic activity including insulin IGF1 IGFBP1 IGFBP3 leptin adiponectin IL-6 TNF-alpha IL1beta as well as the effect of STMF cycles on leukocyte subpopulations with a role in the control of tumor growth such as regulatory T cells the myeloid-derived suppressor cells MDSC as well as NK cells and on stem cell pools eg hematopoietic stem cells endothelial stem cells mesenchymal stem cells
The STMF regimen that is applied is a 5-day low-calorie and low-protein diet Patients undergo a medical examhistory collection and a nutritional assessment body weight handgrip strenght and bioimpedance measurement at baseline and then at the visits that precede every cycle of STMF ie once every three weeks or monthly depending on the therapeutic regimen the patient is undergoing and in any case no more frequently than once every three weeks - eg when combined with q21 chemotherapy regimens Adverse events are recorded at each visit in accordance with NCI-CTCAE version 50 P
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None